Eculizumab is indicated for treatment of patients with paroxysmal nocturnal hemoglobinuria to reduce hemolysis, atypical hemolytic uremic syndrome to inhibit complement-mediated thrombotic microangiopathy, anti-AchR antibody-positive generalised myasthenia gravis, and anti-AQP4 antibody-positive neuromyelitis optica spectrum disorder. It is administered as an intravenous infusion. It is a recombinant humanised monoclonal IgG antibody (IgG2/4𝛋) produced by murine myeloma cell culture. It specifically binds to C5, a complement protein, inhibiting cleavage to C5a and C5b, which ultimately leads to C5b-9. It inhibits the intravascular hemolysis caused by the terminal product in patients with complement-mediated thrombotic microangiopathy in patients with aHUS. The precise mechanism in gMG and NMOSD is unknown, but it is presumed to involve inhibition of antibody-induced complement deposition. 

There are certain risks in pregnant patients suffering from PNH and aHUS being administered Soliris. Published data does not report the presence of eculizumab in human milk, although maternal IgG may be present. No data on the effect on breastfed children or on milk production. Patients’ condition and potential effect on breastfed children need to be considered before deciding on treatment. Safety and effectiveness in pediatric patients have not been established – no apparent age-related differences in geriatric patients. 

Soliris or eculizumab is contraindicated in patients with unresolved Neisseria meningitidis infection and those who are not currently vaccinated against the same infection, unless the risk of delaying the eculizumab treatment outweighs the risks of developing meningococcal infection. Adverse reactions of the treatment include serious meningococcal infections, infusion reactions as well as any other systemic infection. Specific adverse reactions include headache, nasopharyngitis, back pain, nausea, diarrhoea, urinary and respiratory tract infections, peripheral edema, abdominal pain, musculoskeletal pain, among others. 

Pricing and Availability

Eculizumab is not registered in India and, therefore, not easily available through local pharmacies or standard supply channels.
As this is a prescription-only treatment, the price quotation for eculizumab is shared on request, after submission of valid medical documents. For the most current pricing and procurement details, patients or caregivers can contact us directly.

The cost of eculizumab in India may differ depending on market trends, supplier access, and regulatory developments, since the medicine is not approved for commercial distribution in the country. The overall price also varies based on supplier, country of origin, shipping costs, and documentation requirements.

Prices may further fluctuate due to GST/local taxes, currency exchange rates, and changes in manufacturer pricing policies. We assist patients to import eculizumab in India safely and lawfully, ensuring complete compliance with the Named Patient Supply (NPS) program. Our team supports patients through each step—from verifying documents to final delivery.

Access

As Eculizumab is not commercially approved in India, it can only be accessed through the Named Patient Import Program (NPIP). We support patients requiring medicines such as Eculizumab by helping procure them under the Named Patient Supply (NPS) route.

Eculizumab injection is available as one 300 mg/30 mL (10 mg/mL) single-dose vial per carton. 

Import Process

1. Submit a request for your medicine
   Patients or caregivers can share their prescription and treatment details to initiate the request.
2. Apply through Form 12A
   An application in Form 12A must be submitted along with a valid prescription from a Registered Medical Practitioner (RMP).
3. Document verification
   All medical documents and prescriptions are verified to confirm eligibility for importing the medicine in small quantities for personal medical use.
4. Import permission
   Once approval is granted by the Drugs Controller General (India), the import procedure begins as per the prescription.
5. Sourcing the medicine
   Our sourcing team coordinates with authorized international suppliers to find the best available price in India, ensuring product authenticity before finalizing the purchase.
6. Medicine delivery
   After approval and confirmation, logistics are coordinated to ensure safe, compliant, and timely delivery to the patient’s address in India.

Required Documents

To enable the import of Eculizumab to India, patients must provide:

• A valid prescription specifying the medicine name, dosage, treatment duration, and diagnosis.
• Recent medical history and test reports (preferably from the last three months), including those confirming the diagnosis.
• Government-issued ID and proof of residence of the patient.
• Import permit (if applicable).

The order is confirmed only after receiving a valid prescription and the required documents. Once the import permit is approved, the licensed supplier arranges shipment of eculizumab from approved international sources such as the USA, Canada, Europe, or Australia.

Through this process, patients can import eculizumab into India safely and legally. We make the medicine available across major cities, sourcing only from genuine international suppliers to ensure quality and authenticity. We maintain complete transparency in pricing, and all prescriptions are reviewed by registered pharmacists before final dispatch.

Any patients seeking comprehensive information about this medication, including availability and guidance, are encouraged to reach out. For detailed support or pricing assistance, please visit 247qualitymeds.com.